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Abstract: Prostate cancer is the second-most widespread cancer in men worldwide. Treatment 
choices are limited to prostatectomy, hormonal therapy, and radiotherapy, which commonly have 
deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among 
novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. 
However, its use is currently limited by the lack of delivery systems able to selectively deliver 
the therapeutic genes to the tumors after intravenous administration without major drawbacks. 
To remediate this problem, a wide range of nonviral delivery approaches have been developed 
to specifically deliver DNA-based therapeutic agents to their site of action. This review provides 
an overview of the various nonviral delivery strategies and gene therapy concepts used to deliver 
therapeutic DNA to prostate cancer cells, and focuses on recent therapeutic advances made so far.
Keywords: prostate cancer therapy, gene delivery, tumor targeting, nanomedicine
Introduction
Prostate cancer is one of the leading causes of death in men worldwide. It is the 
fourth-most widespread cancer in the world and the second-most common cancer in 
men.1 According to the World Health Organization, prostate cancer is estimated to cause 
1.1 million new diagnosed cases and 307,000 deaths annually worldwide.1 A continuous 
rise in the prostate cancer incidence rate has been recorded, with a threefold increase 
in Europe between 1975 and 2011.2 Around 190,000 new cases arise each year, with 
80,000 deaths occurring annually from prostate cancer.2
Prostate cancer is usually diagnosed at the very late stages of the disease, which 
is one of the factors contributing to its high mortality rate, in addition to the frequent 
failure of localized prostate cancer therapy.3 Unfortunately, prostate cancer patients 
rarely seek diagnosis during the localized stages of the disease, because most notice 
no symptoms other than the ones that resemble those of urinary tract infection.4
In addition, prostate cancer treatment choices are limited, variable in efficiency, 
and can lead to side effects. The selection of the appropriate treatment plan (prostatec-
tomy, hormone therapy, aspecific radiotherapy, and chemotherapy) depends mainly on 
the severity of the case, which determines the purpose of the treatment: either a total 
cure or prolongation of the patient’s life. Patients diagnosed in the early stages of the 
disease have a higher chance of total recovery, while the main goal is to prolong the 
patient’s life in the case of metastasis and relapse.5 However, most of the available 
treatment options are associated with major side effects and have limited ability to 
cure patients in the late stages of prostate cancer. Therefore, in light of the high and 
rising incidence of the disease, the search for new therapeutic approaches, including 
those applicable to metastasis cases, is crucial.
Gene therapy is a new approach used to treat genetic and hereditary disorders, 
such as cancer, Parkinson’s disease, and cystic fibrosis. The US Food and Drug 
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Administration (FDA) defines gene therapy as any product 
that uses a transferred foreign genetic material to produce 
its effects by expressing and/or integrating the gene with 
the host-cell genome for the purpose of cell modification, 
both in vivo and ex vivo. The transferred gene is introduced 
to the host cells using a suitable vector, such as a viral or 
nonviral delivery system, in order to treat genetic mutation 
and regulate cellular processes.6,7
In 2003, the Chinese FDA approved the first gene therapy 
product to treat head-and-neck squamous-cell carcinoma. 
Gendicine is a nonreplicative adenovirus that carries the 
P53 gene. This product created much controversy, due to 
the lack of a Phase III clinical trial.8 Two years later, the 
Chinese FDA approved another gene therapy drug, Oncorine 
(Shanghai Sunway Biotech, Shanghai, China), which is used 
with chemotherapy to treat refractory nasopharyngeal cancer 
using a controlled replicative adenovirus. In 2012, Glybera 
(UniQure, Amsterdam, the Netherlands) was the first gene 
therapy to receive a recommendation for approval by the 
European Medicines Agency. It is an adenoassociated virus 
that carries the lipoprotein-lipase gene to the muscles for the 
treatment of lipoprotein-lipase deficiency.
Although gene therapy is a promising approach for treating 
cancer, it is nevertheless associated with certain limitations 
and challenges that undermine its possible efficacy, thereby 
slowing the speed of its progress as a prominent therapy for 
prostate cancer. A major obstacle to DNA-based therapy is 
the lack of stability of nucleic acids. Naked nucleic acids are 
subjected to nuclease-mediated degradation before they reach 
their target site. Complexing DNA with a nonviral delivery 
system has the potential to increase the stability of the DNA 
and to facilitate the delivery of the DNA to the diseased tissues. 
Another major challenge in the field of prostate cancer therapy 
is the need for systemic delivery and targeting of metastatic 
prostate cancer. Currently, most in vivo gene therapy strategies 
use intraprostatic injection of delivery systems, as this is the 
most efficacious route so far to treat primary prostate cancer 
cells. Although local administration allows a reduction in 
administered dose, it does not target prostate cancer metastasis 
in distant organs. Systemic delivery of a targeted gene delivery 
system could allow the treatment to reach metastases, but an 
intravenously administered nanomedicine would face numer-
ous extracellular barriers (such as interaction with plasma 
proteins and opsonization) before reaching its target. Many 
gene therapy studies are under way worldwide, especially to 
treat cancer, which accounts for 60% of ongoing trials.6
Delivery barriers
Several factors affect the delivery of gene delivery systems to 
cancer cells following intravenous administration.9 These fac-
tors can be classified as extracellular and intracellular barriers 
(Figure 1).
Extracellular barriers
Extracellular barriers correspond to any factors limiting the 
delivery of a nanomedicine, from its administration until it 
reaches the cancer cells. Due to their net positive charge, gene 
delivery systems can undergo aspecific binding to negatively 
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Figure 1 Extracellular and intracellular barriers limiting the delivery of therapeutic genes to nuclei of prostate cancer cells.
Abbreviation: EPR, enhanced permeability and retention.
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charged molecules, such as serum proteins, immunoglobulin 
M, and complement C3, by electrostatic interactions, which 
can lead to macrophage uptake, dissociation of the DNA 
from its carrier, and then degradation of DNA by serum 
endonucleases.9,10 This issue can be overcome by conjugating 
the delivery systems with an anionic hydrophilic molecule, 
such as polyethylene glycol (PEG), to reduce their total 
positive charge and thus decrease aspecific interactions and 
improve transfection ability.10
Another issue that can arise during gene delivery is intake 
of nonviral vectors by the immune cells, which identify them 
as foreign entities.9 Nonviral vectors are usually less immu-
nogenic than viral vectors. Nevertheless, a nonviral delivery 
system complexed with DNA can still face an immunoreac-
tion, due to the unmethylated cytosine guanine (CpG) sites in 
the condensed gene. This immunoresponse can be diminished 
by eliminating unnecessary CpG sites from the complexed 
gene or reducing the administration dose.10
Intracellular barriers
Intracellular barriers can be categorized as any factors at 
the cellular level that lead to a reduction in the efficiency 
of the gene therapy. The first cellular obstacle that can face 
gene delivery systems when they reach the targeted cells is 
their uptake efficiency. Gene delivery systems are gener-
ally taken up by cells via receptor-mediated endocytosis, 
a cellular biological process whereby a specific molecule can 
enter the cell with the assistance of a specific receptor in the 
cell membrane. The endocytosis process, or endocytic path-
way, can be considered a barrier to gene delivery, since its 
efficiency can be affected by several parameters, such as the 
size of the delivery system. It has been observed that delivery 
systems 50 nm show significant uptake by cells through 
endocytosis compared with delivery systems 50 nm, with 
optimum size being 25 nm.11
The second cellular barrier takes place during the cellular 
uptake of the delivery system, when the delivery system–
receptor complex is trapped inside an endosomal sack. In 
the endosome, the delivery system and its carried genetic 
material may undergo degradation by lysosomal nucleases 
in a low-pH environment.9,12 In overcoming this limitation, 
gene delivery systems tend to escape from the endosome 
through the proton-sponge effect, which is initiated by the 
acidic pH of the endosome. The low pH increases the ioniza-
tion of the delivery system (cationic polymer or dendrimer), 
then the ionized polymer attracts protons to the endosome, 
leading to an increase in osmotic pressure, endosomal swell-
ing, and disruption, which releases the therapeutic DNA in 
the cytoplasm.10,12
Following endosomal escape, up to 99% of the DNA may 
be degraded by cytoplasmic nucleases if it stays for a long 
time in the cytoplasm. The last obstacle to gene delivery is 
effective nuclear uptake of the DNA. Nuclear transport is 
controlled by the nuclear pore complex, which is permeable to 
molecules of size 70 kDa (10 nm in diameter).10 DNA can be 
taken up by the nucleus by either passive or active transport. 
Passive transport occurs during cell division, during which 
the nuclear envelope lyses, allowing the genetic material to 
be transported to the nucleus. In active transport, nuclear 
localization signals bind to the nuclear pore complex to allow 
larger DNA molecules to pass through these pores.12
Gene delivery systems
For gene therapy to be successful, therapeutic DNA must 
successfully cross the cell membrane and then integrate with 
the nucleus genome of the targeted cell. However, naked 
DNA cannot achieve this without undergoing degradation 
during its passage through the blood circulation and bio-
logical tissue.13 Moreover, a charge repulsion can be created 
between the naked DNA and the cell membrane, due to their 
common negative charges, which can hinder the cellular 
uptake of DNA.7
These drawbacks can be overcome by using a suitable 
gene delivery system. Gene delivery can be simply defined 
as a process to introduce a foreign gene to a host cell using 
a gene carrier. It involves the complexation of the gene of 
interest to a suitable gene delivery vector, in order to facilitate 
its transfection to the targeted cells.13 The main challenge in 
gene delivery is to find an effective delivery system able to 
target the required tissue and deliver the transferred gene 
to the cells without secondary side effects. Gene delivery 
confers several advantages on the complexed DNA, such 
as protection from degradation in blood circulation and 
increased targeting specificity to the required tissue. Viral 
and nonviral delivery systems can be used to transfer DNA 
to cancer cells.
Viral delivery systems
Viruses are highly efficient at transferring their own genome 
to the host cells. This unique ability has been used to transfer 
therapeutic genes to specific cells.14 Modified (replication-
deficient) viruses are used as gene vectors to attenuate their 
ability to induce infection.15 The use of viruses as gene 
vectors has several advantages. First, viruses have a strong 
ability to pursue and attach to specific cells. They also exhibit 
high efficiency at introducing genetic material into cells. 
Furthermore, viral vectors are found to integrate genes into 
target cells for a longer period than nonviral vectors.16
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On the other hand, the use of viral vectors is severely 
hampered by disadvantages, such as immunogenicity. The 
immune system can identify a virus as a foreign substance 
and initiate an immunoresponse against it, especially if the 
patient has previously been exposed to that virus. This immu-
noreaction thus reduces the ability of the viral vector to reach 
the target cells and to achieve successful gene delivery.16 
In addition, viral vectors suffer from a limited ability to 
condense and transfer large DNA molecules.7 Using viruses 
as gene delivery systems can also potentially lead to toxicity 
and oncogenicity.17 Because of these limitations, this review 
thus focuses on the use of nonviral gene delivery systems for 
the treatment of prostate cancer.
Nonviral gene delivery systems
A variety of nonviral delivery systems, such as liposomes 
and polymers, have been tested for gene delivery to pros-
tate cancer (Figure 2). The majority of nonviral vectors can 
condense DNA via electrostatic interactions,7 resulting in 
such advantages as protection of the DNA from degrada-
tion by the nuclease enzymes present in the circulation.7,9 In 
addition, DNA complexation reduces the charge repulsion 
that arises from the charge similarity between the DNA and 
cell membrane, which in turn facilitates the delivery of the 
DNA inside the cells.10 Furthermore, nonviral vectors possess 
higher ability to complex large DNA molecules when com-
pared to viral vectors, due to their well-constructed chemical 
structure comprising cationic functional groups. In addition, 
the targeting ability of nonviral vectors can be improved by 
using targeting ligands able to recognize specific receptors 
in the target tissue.
Liposomes
Liposomes were first described in 1965 as a chemical formu-
lation comprising a phospholipid bilayer with a hydrophilic 
head and hydrophobic chain, forming an overall spherical 
shape.18 Due to their unique chemical nature, they can be 
used as carriers for drugs and genes: hydrophilic compounds 
are encapsulated in the inner part of the liposome, while 
lipophilic substances can be trapped in the lipid bilayer. This 
gives liposomes the ability to transfer different substances 
through the blood circulation.13
In 1987, Felgner et al first designed a cationic lipo-
somal system using the double-strain monovalent 
quaternary ammonium N-[1-(2,3-dioleyloxy)propyl]-N,N,N- 
trimethylammonium chloride (DOTMA) to carry genetic 
material. This forms a complex called a lipoplex, which is 
initiated by the electrostatic interactions between negative 
phosphate groups in the genetic material and positive amino 
groups in the liposome, thereby leading to the condensation 
of DNA.19 Several factors contribute to lipoplex charac-
terization, such as shape, size, and surface charge. These 
properties can be controlled by physical methods to improve 
transfection. The surface-charge ratio is the most important 
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Figure 2 Nonviral gene delivery systems and therapeutic strategies for prostate cancer therapy.
Abbreviation: EPR, enhanced permeability and retention.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
9.
82
.1
79
 o
n 
26
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5757
Targeted nonviral gene therapy in prostate cancer
parameter: cationic liposomes should have a higher net 
charge than DNA, so that the DNA complexation with the 
vector forms a total surface-charge ratio around one. This 
criterion creates full protection from degradation for the DNA 
and assists its penetration into cells, due to charge attraction 
between the lipoplex and cell membrane.7,16
Liposomes are associated with some limitations to their 
DNA-transfer capability, which can be overcome by various 
modification methods. First, liposomes tend to have a short 
circulation half-life in the bloodstream, due to their rapid 
clearance from the body. The rate of clearance is affected 
by the size, charge, and membrane composition of the lipo-
some. Large liposomes tend to have a faster clearance rate, 
due to the high serum protein opsonization in the liposomal 
membrane during its circulation in bloodstream, and hence 
the opsonins in the liposome surface trigger its uptake via 
phagocytosis.20 In order to improve circulation half-life, 
liposomes can be chemically modified by conjugation with 
a ligand. For example, the conjugation of PEG with lipo-
somes leads to the formation of long-circulating, sterically 
stabilized liposomes, which have a longer half-life and thus 
better targeting ability than regular liposomes. Circulation 
time is prolonged by the inability of macrophages to remove 
these molecules, because they are less able to detect the modi-
fied liposomes. PEG in the liposome surface impedes the 
coupling of opsonins with the liposome surface, thus reducing 
the ability of phagocytes to recognize the liposomes.18 With 
longer circulation time, the ability of liposomes to deliver 
the transferred DNA to the targeted tissue tends to increase 
severalfold, which improves the targeting of poorly acces-
sible tissue, such as solid tumors.18
Secondly, the targeting proficiency of liposomes is not 
specific enough when compared with viral vectors, which 
tend to have high targeting ability, but it can be improved 
by conjugating an antibody to the liposome in order to 
target specific tissue. Antibody-coupled liposomes, also 
called immunoliposomes, can be removed easily from the 
circulation if not combined with PEG to form stabilized 
immunoliposomes.21 However, some disadvantages arise 
from the use of antibodies with liposomes, such as a pos-
sible immunoreaction, especially when using a high antibody 
concentration.
Finally, gene transfection efficiency varies among dif-
ferent types of liposomes, monovalent liposomes being the 
least efficacious. Neutral colipids such as dioleoylphosphati-
dylethanolamine (DOPE) and cholesterol can be linked to 
the cationic liposome to improve the liposomal transfection 
process through the cell membrane. Colipids promote the 
fusion of the endosomal membrane, facilitating endosomal 
escape and the release of DNA into the cytoplasm.22 They also 
facilitate the release of DNA from the lipoplex. Furthermore, 
colipid binding is critically important in improving the gene 
transfection of monovalent cationic liposomes, while its main 
effect with multivalent liposomes is to reduce the toxicity 
that might arise from their high charge ratio.7
Cationic polymers
Cationic polymers are macromolecules that possess positive 
charges due to their high density in amine groups. Among 
the different types of cationic polymers developed in recent 
years are neutral polymers (eg, chitosan), polypeptides 
(eg, poly-L-lysine [PLL]), and dendrimers (eg, polyamido-
amine [PAMAM]). Some chemical modifications can be 
applied to these polymers to improve their efficiency as vec-
tors and reduce their toxicity via the use of binding ligands. 
Polymers can be used as gene carriers, as their positively 
charged groups can form electrostatically attractive forces 
with the negatively charged phosphates in the DNA. The 
complex formed, called a polyplex, protects the complexed 
DNA from hydrolysis in the circulation or tissue, giving it a 
longer half-life and improved targeting.16
Several criteria can affect the efficiency of the polyplex. 
For example, a higher molecular-weight polymer provides 
superior condensation of the genetic material. Another 
important factor that can contribute to polyplex efficiency 
is the charge ratio, which is a parameter used to calculate 
the nucleotide equivalence using the ratio of nitrogen (in the 
polymer) to phosphate (in the DNA). The total charge should 
be positive in order to form a stable and effective polyplex. 
Although the charge ratio is important, it should be limited to 
a certain extent. A high total positive charge on the polyplex 
can have various side effects, such as increased systemic 
cytotoxicity of the polyplex and random interaction between 
the polyplex and biological membranes, thus attenuating 
targeting ability and causing a loss of specificity.23 In order 
to overcome these problems, a polypeptide, such as PEG, can 
be conjugated to the polyplex to reduce the overall charge 
ratio without affecting its gene complexation capability.23 
Alternatively, the high-charge problem can be overcome by 
the use of newly designed cationic polymers with hydroxyl 
or amide groups, such as poly(vinyl alcohol) dimethylam-
inoacetal (PVA3), that have been shown to have effective 
gene transfer, less toxicity, and increased DNA release in 
the cytoplasm. This effect can be explained by a decrease in 
the total positive charges of the complex or the formation of 
hydrogen bonds between the DNA and hydroxyl groups.13
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Examples of cationic polymers used for treatment of 
prostate cancer
PLL is a polypeptide cationic polymer that is one of the early 
polymeric vectors used in gene delivery. PLL contains a high 
density of primary amines that have a strong affinity with 
negative ions at neutral pH, since most of them are ionized 
at pH 7.4.24 The use of PLL as a gene carrier is associated 
with certain limitations. For example, its gene transfection 
ability is weak at biological pH, due to the strong interac-
tion between DNA and PLL, which prevents the release of 
DNA to the cytoplasm. Additionally, the chemistry of PLL is 
associated with a certain immunogenicity and toxicity, due to 
its amino groups. The modification of PLL with ligands can 
reduce its side effects and improve its ability as a gene carrier, 
especially in in vivo trials, since it is biodegradable.24
Another cationic polymer that is commonly used as a 
vector in gene delivery is polyethylenimine (PEI). Its unique 
chemical structure, comprising a nitrogen atom to every three 
atoms, promotes its DNA-complexation ability to form a 
stable polyplex, as well as a strong ability to condense large 
molecules.25 At pH 7.4, only 17% of the nitrogen groups 
in PEI are ionized. This gives PEI several advantages. 
It has superior DNA condensation ability with high gene-
transfection capability, since it can easily release DNA into 
the cytoplasm. Moreover, the low protonated PEI facilitates 
endosomal escape of the polyplex from the lysosome by 
means of the proton-sponge effect.26
Another polymer, poly(B-amino ester), has also been 
used in prostate cancer therapy. It is a biodegradable polymer 
that is able to self-assemble with DNA to form positively 
charged gene delivery nanoparticles. The main advantage of 
this polymer is its ability to hydrolyze in acidic and alkaline 
media, which facilitates the release of DNA inside cells. 
Furthermore, both the polymer and its degradation products 
have been shown to be nontoxic.27
Dendrimers
Dendrimers are three-dimensional branched macromolecules 
with a treelike structure. Their name originates from the Greek 
word ‘dendron’, which means “tree”. Since their discovery, 
dendrimers have been widely used in various applications 
in pharmacy, medicine, and engineering.28–31 Their chemical 
structure is composed of two parts: a reactant core molecule 
that is considered the origin of the dendrimer, and highly 
branched polymers that bind to the core in a specific way to 
form a uniformly branched spherical macromolecule.31
The use of dendrimers in gene delivery is restricted to 
cationic dendrimers, such as PAMAM and diaminobutyric 
polypropylenimine (DAB) dendrimers. Cationic dendrim-
ers complex the genetic material by electrostatic interactions 
between the phosphate groups on the DNA and the amino groups 
on the dendrimer. Among their advantages over regular poly-
mers, dendrimers have generally enhanced gene-transfection 
ability, which increases with higher generations.13 Their tree-
like shape also increases the surface area of the molecule and 
creates inner cavities, thus improving their DNA-complexation 
and drug-encapsulation capability. Additionally, dendrim-
ers have been found to be nonimmunogenic molecules, 
which makes them suitable gene carriers for in vivo studies.31
Cancer targeting
Passive targeting
Passive targeting is a naturally occurring process that arises 
from the unique pathophysiology of the tumor site. Due to the 
nature of the blood vessels formed and disruption of lymph-
node function, macromolecules and nanoparticles tend to 
accumulate in tumor tissue. This is called the enhanced 
permeability-and-retention effect or passive targeting.32 Its 
efficiency is affected by several factors, such as the vascu-
lar permeability of the tumor blood vessels and the size of 
macromolecules, which control their diffusion to cancer 
tissue. Most blood vessels in cancer tissue have a diffusion 
permeability of 200–2,000 nm, depending on the location 
and the type of the tumor.32
Active targeting
Active targeting is a method allowing the specific delivery 
of nanomedicine to an organ, tissue, or cell by chemically 
conjugating the delivery system with a specific ligand that 
has the ability to bind to a specific binding site in the targeted 
tissue. The ligand could be a protein, antibody, or sugar, 
while the targeted binding site could be a receptor, sugar, 
protein, or lipid that is highly expressed on the surface of 
the targeted cancer cells.32
Prostate cancer-targeting ligands
Iron-binding proteins
Transferrin (Tf) and lactoferrin (Lf) are iron-binding proteins 
that have been found to be overexpressed on various cancer 
cells, including prostate cancer cells. The main function of 
these proteins is to control the free iron level in the blood 
and body fluids. High iron levels increase the risk of bacte-
rial invasions, as well as free-radical generation, which is 
associated with the conversion of ferrous ion (Fe2) to ferric 
ion (Fe3) in the body.33 Several studies have used Tf and Lf 
as targeting ligands in prostate cancer therapy.34–36
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Integrins
Integrins are transmembrane glycoprotein receptors that 
link the cytoskeletons of cells with the extracellular matrix 
(ECM). They act as adhesion, migration, and signaling mol-
ecules, connecting cells to the ECM by binding with such 
proteins as fibronectin, vitronectin, and collagen.37,38 These 
adhesive molecules assist the connection between adjacent 
cells and surrounding ECM by creating tunnel-like junctions 
maintained by integrins, which facilitate the passage of ions 
and small molecules between cells and form and break as 
needed.39 Integrins also act as signaling molecules between 
cells in a given tissue, and between cells and the ECM.
Several integrin receptors have been found to be overex-
pressed in prostate cancer cells, with differentiation in their 
expression as the cancer progresses, whereas other receptors 
have been detected only in cancer tissue. The integrin het-
erodimer receptors ANB6, ANB3, AIIbB3, A6B1, A5B1, and A6B4 
have been shown to be overexpressed in prostate cancer.40,41 
Among these, ANB3 has been found to be expressed in prostate 
cancer cells at an intensity that varies with the metastatic and 
invasion tendency of the cells. PC3 cells extensively express 
ANB3, while LNCaP cells do not, explaining the higher inva-
sion capability of PC3 over LNCaP cells, as ANB3 tends to 
adhere to vitronectin in the ECM.42 In addition, A
5
B
1
 has been 
shown to be expressed in PC3 cells, as it has a role in their 
adhesion and invasion behavior.43
3URVWDWHVSHFLÀFPHPEUDQHDQWLJHQ
Prostate-specific membrane antigen (PSMA), or glutamate 
carboxypeptidase II, is an integral transmembrane glyco-
protein with a molecular size of 100 kDa. It was first identi-
fied on the prostate epithelial membrane in 1987, when a 
newly developed antibody (7E11) was able to recognize the 
N-terminal portion of the protein in prostate tissue, hence 
its common name.44,45 PSMA is expressed primarily in all 
forms of prostate tissue and has low expression in the nervous 
system, liver, kidney, and small intestine. More importantly, 
it has been found to be expressed in solid tumors, such as 
prostate, lung, breast, and colon cancer.46,47 Although PSMA 
has been detected in several tumor types, it is uniquely 
overexpressed in prostate cancer, which makes it a suitable 
biomarker to be investigated in therapeutic and diagnostic 
applications. It is strongly expressed in both primary and 
metastatic cancer cells, and its expression increases with the 
malignancy of the disease.48
PSMA expression in prostate cancer cells has been 
found to be correlated with androgen sensitivity. Cells of the 
androgen-sensitive LNCaP epithelial cancer cell line express 
PSMA in their membranes. Conversely, PC3 and DU145 
metastatic cancer cells in bone and brain, respectively, were 
found not to express PSMA, although its DNA and mRNA 
have been detected in these cells.49 Although there is still 
no known natural ligand that can bind to PSMA, several 
researchers have succeeded in preparing synthetic binding 
antibodies and peptides with good ability to bind to the 
extracellular domain of PSMA.45,50
Prostate stem-cell antigen
Prostate stem cell antigen (PSCA) is a prostate-specific 
cell-surface antigen that is overexpressed in both androgen-
dependent and -independent prostate cancer cells, making it 
a suitable marker for prostate cancer. Taylor et al51 examined 
the mRNA expression of different prostate cancer-targeting 
motifs, including PSCA, which was found to be overex-
pressed. Garcia-Hernandez et al52 vaccinated mice with 
PSCA-based vaccine to induce long-term protection against 
prostate cancer. The vaccination increased the expression of 
some cytokines (IFNG, TNFA, and IL2), which was an indi-
cation of the successful generation of an immunoresponse 
against prostate cancer in the vaccinated mice.
Others
There are several other possible ligands that can target pros-
tate cancer. HER2 is a potential target, due to its overexpres-
sion in various tumors, including prostate cancer.53 Mucin 1 
is a membrane glycoprotein that has positive expression in 
prostate cancer tumors compared with healthy tissue, making 
it a suitable target for prostate cancer treatment.54
Therapeutic strategies
Cancer is considered a genetic disorder, as various genetic 
mutations affect several genes in cancerous cells. Those 
mainly affected are tumor-suppressor genes (eg, TP53 
and NM23) and oncogenes (eg, RAS, c-MYC, BCL2, and 
c-MET ).55,56 Tumor-suppressor genes are responsible for the 
regulation of normal cell death and cellular waste-product 
removal. Their inactivation by either disappearance or muta-
tion can promote cell malignancy. Oncogenes are responsible 
for consistent cell growth. Their activation can boost cancer-
cell growth.16
In prostate cancer, various genes are involved in genetic 
mutations. For example, the tumor-suppressor genes TP53 
and retinoblastoma were found to be mutated in around 50% 
and 35% of advanced prostate cancer cases, respectively. 
The main functions of TP53 are to regulate the cell life 
cycle and repair any disruption in the DNA, and the result 
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of a mutation of this gene is uncontrolled cell growth.55,57 
In addition, the GSTP1 gene was found to be disrupted in 
some prostate cancer cases. The main cellular role of GSTP1 
is carcinogen detoxification, and its inactivation leads to 
carcinogenesis.56,57
Various gene therapy strategies can be involved in 
prostate cancer treatment, such as gene apoptosis therapy, 
in which the transformed gene is replaced with one that 
regulates cancer cell death, corrective gene therapy, which 
uses a tumor-suppressor gene to restore normal cell-growth 
regulation, immunomodulatory gene therapy, which uses 
genes to stimulate the immune system, and suicide-gene 
therapy, which relies on introducing genes that cause changes 
to a chemical compound or enzyme to form toxic substances. 
An overview of the ongoing studies based on nonviral gene 
delivery systems and therapeutic approaches against prostate 
cancer is presented in Table 1.
Apoptosis-inducing gene therapy
Apoptosis is a normal physiological process that is pro-
grammed under certain circumstances to control cell death.58 
In normal cells, it is usually generated to eliminate cells that 
have sustained genetic mutation or damage. The suppression 
of cellular apoptosis is one of the common problems gener-
ated by genetic mutation in cancer cells, leading to cancer 
development. Therefore, using gene therapy to induce cel-
lular apoptosis in cancer cells would be an effective treatment 
for cancer.
TNF superfamily cytokines (TNFA, TRAIL, and FasL) 
are the most common cytokines to cause cellular apoptosis by 
binding to their specific death receptors.59 Caspase activation, 
which occurs externally (by binding to the death receptor) 
or internally (via the mitochondria and death domain), is 
required for stimulating cell apoptosis.58,60
Extrinsic apoptosis activation occurs through activation 
of the transmembrane death receptors (TNF receptors). 
The activation initiated by the specific binding of death 
ligands, such as the TNF-protein family or FasL to their death 
receptors TNFR1, TNFR2 and Fas receptor respectively, 
which creates a particular binding site specific to the adaptor 
protein. This causes the formation of a death-inducing signal-
ing complex (DISC), triggering the activation of caspase 8, 
which in turn causes cell apoptosis through activating effector 
caspases such as caspase 3 and 6, which have the ability to 
recognize proteins’ amino-acid sequences involved in the 
main cellular functions and cleave them at specific motifs 
to form substrate residues.58,60
Alternatively, the intrinsic activation pathway can arise 
in the cell itself, due to genetic damage, oncogene activa-
tion, or any stress condition. It initiates from mitochondria 
or endoplasmic reticulum. In the mitochondrion, mitochon-
drial membrane permeability is controlled by a protein 
family called Bcl2. After apoptotic stimulation, this causes 
the release of cytochrome C, followed by the apoptosome, 
leading to the release of Apaf1 and then activating the ini-
tiator caspase 9 followed by the effector caspase 3, which 
initiates cell apoptosis.60 Some cytokines are well known to 
cause apoptosis of inflamed and mutated cells.60 Using this 
mechanism to suppress cancer has been found to lead to 
promising outcomes.58,61,62 Some common cytokines used 
for this purpose are TNFA, TRAIL, and FasL.
Tumor-necrosis factor-A
TNFA is an inflammatory cytokine that produces many bio-
logical activities in the immune system, at inflammation sites, 
and in cell death and survival.63 To generate cell apoptosis, 
TNFA couples with its binding receptor (TNFR1), which is 
expressed in most tissue and leads to activation of the death 
domain in the cytoplasm (TRADD) and Fas-associated death 
domain (FADD). This leads to the formation of DISC, which 
activates procaspase 8, thereby causing DNA fragmentation 
and cell apoptosis.64
High TNFA levels cause cell apoptosis and necro-
sis, a property that can be used to destroy cancer cells.64 
Table 1 Summary of prostate cancer-targeted gene therapy studies using nonviral vectors
Targeting ligand Delivery system Genes and drugs Results Reference
Transferrin DAB dendrimer (generation 3) TNF, TRAIL, IL12 Tumor regression/suppression 44
Lactoferrin DAB dendrimer (generation 3) TNF, TRAIL, IL12 Tumor regression/suppression 47
PSMA inhibitor PEI polymer TRAIL ÁXRURF\WRVLQH 
bacterial cytosine deaminase
Tumor-growth inhibition 57
None PAMAM dendrimer FASL  cisplatin Tumor-growth inhibition/tumor regression 60
None PLGA polymer TP53 Tumor regression (IT), tumor-growth  
inhibition (IV)
66
Transferrin Cationic liposomes TP53 Tumor-growth inhibition 67
Abbreviations:'$%GLDPLQREXW\ULFSRO\SURS\OHQLPLQH360$SURVWDWHVSHFLÀFPHPEUDQHDQWLJHQ3(,SRO\HWK\OHQLPLQH3$0$0SRO\DPLGRDPLQH3/*$SRO\ODFWLF
co-glycolic acid); IT, intratumoral; IV, intravenous.
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Mauceri et al used the TNFA gene to treat epidermoid carci-
noma, together with targeted radiation therapy. Their results 
showed highly selective tissue necrosis, with no damage to 
normal tissue. DNA encoding TNFA has been used before 
in various studies to treat different cancerous tumors, either 
alone or in combination with such therapies as radio- or che-
motherapy, using various types of gene carrier, mostly viral 
ones. Delivering the TNFA gene using viral vectors to target 
different cancer models by intratumoral65 or intravenous 
injection66 results in significant inhibition in tumor growth, 
but without tumor suppression.
TNFA cytokine therapy was also tested against prostate 
cancer when Chopra et al64 investigated the effects of TNFA 
on normal and cancerous (LNCaP) prostate cells in vitro. 
The results for low doses of TNFA were promising, with 
significant (90%) LNCaP cell apoptosis and no effect on 
normal cells. In another study, Chung et al67 treated nude 
mice bearing xenograft prostate tumors using a combination 
of radiotherapy together with TNFA carried by an adenovi-
rus injected intravenously, resulting in regression of tumor 
volume compared to gene therapy or radiotherapy treatment 
alone. In addition, studies have discussed the impact of inhib-
iting NFKB to improve the sensitivity of prostate cancer cells 
toward TNFA apoptosis by using PMS1077 and apigenin.68,69 
Using a nonviral delivery system, we demonstrated that 
intravenous administration of Tf-bearing DAB dendriplex 
encoding TNFA resulted in tumor eradication of 60% of 
PC3 and 50% of DU145 tumors.34 This tumor-targeted TNFA 
gene therapy was more efficacious than TRAIL and IL12, 
leading to tumor regression and even some tumor disap-
pearance. To our knowledge, it was the first time that the 
intravenous administration of tumor-targeted dendriplexes 
encoding TNFA, TRAIL, and IL12 on mice bearing prostate 
tumors inhibited tumor growth and even led to complete 
tumor suppression in some cases. In a further study, we 
recently replaced the tumor-targeting ligand Tf with Lf, an 
iron-binding member of the Tf family that has been shown 
to have intrinsic antitumoral activity, making it particularly 
attractive as part of gene medicine. Lf binds to specific recep-
tors (LfR1, LfR2) or to Tf receptors overexpressed on most 
cancer cell lines.70,71 This novel intravenously administered 
Lf-bearing DAB dendriplex-encoding TNFA resulted in 
improved tumor eradication of 70% of PC3 cells and 50% of 
DU145 cells compared to a Tf-bearing dendriplex.36
Tumor necrosis factor-related apoptosis-inducing 
ligand
TRAIL or Apo2L is a transmembrane protein found in 
human tissue, such as the spleen, prostate, and ovaries. 
TRAIL binds to its specific receptors TRAILR1 (death 
receptor 4) and TRAILR2 (death receptor 5), causing activa-
tion of the death domain and cell apoptosis.72,73 In addition, 
TRAIL has also been found to bind with TRAILR3 (TRID/
DcR1) and TRAILR4 (DcR2) decoy receptors, which do 
not contain any cytoplasmic death domain and thus cannot 
induce cell apoptosis. Therefore, binding TRAIL to these 
receptors acts as an antagonist, because it will not activate 
any cell-death signaling. The existence of TRAILR3 and 
TRAILR4 in the cells is linked to their TRAIL-apoptosis 
resistance.74
The mechanism by which TRAIL induces apoptosis 
occurs mainly through the extrinsic pathway when TRAIL 
binds to TRAILR1 or TRAILR2 receptors, which as a result 
stimulates a TRAIL-signaling cascade by forming a DISC. 
The DISC includes several proteins, such as FADD and 
procaspases 8 and 10. Therefore, after TRAIL binding and 
DISC activation, caspase 8 activation is initiated and so are 
caspases 3, 6, and 7. Caspase activation leads to the cleavage 
of target proteins responsible for preserving cellular function, 
resulting in cell apoptosis.73,74
The use of TRAIL as an agent to kill cancer cells arises 
from its preferential ability to induce cell apoptosis in cancer 
cells without harming normal healthy cells.75,76 Ashkenazi 
et al72 examined the apoptotic effect of TRAIL in various 
normal and cancerous cells. It was found to have good 
apoptotic activity against most cancer cells in vitro (32 of 
39 cell types) and was not cytotoxic to normal cells. This 
important characteristic led to further investigations of the 
antitumor activity of this cytokine. Moreover, TRAIL caused 
a significant reduction in tumor progression in vivo, with an 
increase in survival rate. Yu et al75 also examined the effect 
of TRAIL cytokine in vitro in androgen-insensitive PC3 and 
DU145 prostate cancer cells. A TRAIL dose of 200 ng/mL 
resulted in 70% cell death in both cell lines. The study also 
investigated the mechanism behind the TRAIL effect, which 
was found to be the activation of caspase 8 and 3 by cross-
linking and through the death receptors (DR4 and DR5).
Griffith et al77 were the first to introduce TRAIL cDNA 
instead of the cytokine delivered by adenovirus (Ad5-
TRAIL) to examine its possible apoptosis effect against 
PC3 prostate cancer cells. In vitro, treating cells with 
Ad5-TRAIL showed an antiproliferative effect similar to 
that obtained using TRAIL cytokines, whereas other non-
therapeutic DNA carried by the same carrier did not show 
any cytotoxic effect. This study also demonstrated the 
successful production of TRAIL protein in PC3 cells after 
infecting it with Ad5-TRAIL. Later, various researchers 
used adenovirus and adenoassociated virus as carriers for 
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the gene encoding TRAIL to target prostate cancers, both 
in vitro and in vivo.78–80 These treatments resulted in the 
induction of cellular apoptosis in vitro and suppression of 
tumor growth in vivo.
To avoid the immunogenicity problem associated with 
viral vectors, the use of nonviral gene carriers to carry 
DNA encoding TRAIL for prostate cancer therapy has been 
reported. Chen et al81 developed a theranostic nanoplex 
allowing combined TRAIL pDNA gene therapy and prodrug 
enzyme treatment. PEI was used as the delivery system. 
In addition to the TRAIL pDNA, the nanoplex carried the 
prodrug enzyme bacterial cytosine deaminase, which is 
able to convert the nontoxic prodrug 5-fluorocytosine to the 
cytotoxic anticancer drug 5-fluorouracil. Furthermore, a urea-
based small-molecule inhibitor of PSMA, was conjugated to 
the nanoplex for prostate cancer targeting. The combination 
strategy of TRAIL gene therapy and 5-fluorocytosine/bacte-
rial cytosine deaminase treatment demonstrated significant 
inhibition of the growth of PC3-PIP prostate tumors: fol-
lowing intravenous administration of the nanoplex, tumor 
volumes increased to only 300% compared to the 700% 
increase observed following treatment with saline solution 
as a control at day 10 after injection.
In another study using TRAIL gene therapy as sole 
therapeutic strategy, we demonstrated that treatment with 
intravenously injected DAB-Tf dendriplex encoding TRAIL 
led to tumor eradication of 10% of PC3 tumors in mice bear-
ing subcutaneous tumors.34 The replacement of Tf by Lf as 
the tumor-targeting moiety further increased the therapeutic 
efficacy of the system, leading to tumor eradication of 40% 
of PC3 tumors and 20% of DU145 tumors. The enhanced 
therapeutic efficacy observed with DAB-Lf dendriplex treat-
ment extended mouse survival by up to 21 days compared 
to untreated animals.36
Fas ligand
FasL (Apo1 or CD95) is a 40 kDa membrane protein that 
belongs to the TNFA family. Since its discovery in 1989, 
the FasL cellular apoptotic effect has become the focus of 
many studies. FasL binds to its specific receptors in the cell 
membrane Fas, thereby initiating a number of events leading 
to cellular apoptosis. The mechanism by which FasL induces 
cell death is instigated by Fas binding, which causes the 
clustering and trimerization of Fas that trigger the activation 
of DISC in the cytoplasm and in turn activate FADD and 
procaspase 8. Caspase 8 activation triggers the release of 
caspases 3 and 7, which causes the cleavage of vital cellular 
proteins through protease activation.82,83
A key criterion that makes FasL a desirable apoptosis 
inducer is the bystander effect of its transfected gene. There-
fore, successful transfection of the FASL gene to some cancer 
cells would be therapeutically sufficient, as it would infect 
adjacent cells such that cells in neighboring tissues will hold 
the same effect.84 This feature can help overcome weak tar-
geting obstacle in gene delivery. Hyer et al85 and Xiong et al86 
examined the bystander effect of the FASL gene carried by an 
adenovirus in prostate cancer cells. Flow cytometry analysis 
of prostate cancer cells treated for 6 hours with FASL carried 
by an adenovirus demonstrated that there was roughly a 25% 
increase in apoptosis of labeled cells compared with control 
cells. The mechanism believed to cause this bystander effect 
to surrounding cells emanates from apoptotic cellular debris 
and apoptotic vesicles of infected cells, regardless of FasL-
Fas binding status in these cells.
FASL gene delivery and its apoptosis effect have been 
examined against different cancer types, including prostate 
cancer, both in vitro and in vivo. An adenovirus was the car-
rier of choice for most of these studies. In prostate cancer, 
significant tumor growth inhibition, with tumor regression 
in some cases, was detected after intratumoral injections.86,87 
Xiong et al86 treated prostate xenograft tumors with intra-
tumoral injections of FASL carried by an adenovirus, and 
recorded significant tumor growth suppression, with 25% 
of tumors completely disappearing.
Studies have also reported the use of nonviral delivery 
systems for FAS gene therapy in prostate cancer. Nakanishi 
et al84 used the PAMAM dendrimer to condense plasmid 
DNA encoding FasL. Intratumoral injection of FASL DNA 
(10 Mg/injection) complexed with PAMAM (ratio 1:10) led 
to a decrease in growth rate of PC3 tumors and regression of 
LNCaP tumors in mice bearing subcutaneous tumors. In order 
to obtain a more pronounced therapeutic outcome, a PAMAM 
dendriplex encoding Fas was combined with the chemothera-
peutic drug cisplatin. Intratumoral administration of FAS 
gene therapy combined with intravenously administered 
cisplatin limited the growth of PC3 tumors, thus extending 
the survival of tumor-bearing mice. The therapeutic effect 
resulting from the combination therapy was enhanced com-
pared to gene therapy or chemotherapy alone.
Corrective gene therapy
In corrective gene therapy, a defective or absent gene is 
replaced by a therapeutic one. The most common tumor-
suppressor gene found mutated or absent in prostate cancer 
is TP53, which has been selected as a target in this treat-
ment approach with nonviral delivery systems.88 TP53 is a 
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tumor-suppressor gene that plays an important role in genome 
stability through different cellular mechanisms. It has been 
found to be mutated in around 50%–75% of prostate cancer 
cases,89 resulting in an increase in cancer cell resistance to 
chemotherapy and radiotherapy.
Nonviral gene carriers, such as polymers and liposomes, 
have been used to deliver p53 to prostate cancer cells. Sharma 
et al90 developed biodegradable nanoparticles based on 
poly(lactic-co-glycolic acid) polymer for sustained delivery 
of the TP53 gene and examined their therapeutic efficacy 
against PC3 xenograft tumors following intratumoral and 
systemic administration. Intratumoral injections of this for-
mulation resulted in significant tumor regression after only 
one dose, whereas intravenous injection showed a decrease in 
tumor growth, but without regression. In another study, Seki 
et al91 used Tf-bearing cationic liposomes to target prostate 
cancer. This intravenously injected formulation led to signifi-
cant tumor-growth suppression compared to controls.
Immunomodulatory gene therapy
Cancer cells are well known to have a weak ability to 
elicit an immunoresponse, which reduces the immune 
system’s ability to identify and destroy cancer cells. The 
poor immunogenicity of cancer cells arises from the weak 
expression of major histocompatibility complex antigens 
in their cell membranes. These antigens are responsible for 
T-cell activation, which is the initial step in generating an 
immunoreaction. Furthermore, in several tumor types, cancer 
cells release certain immunosuppressive molecules, such as 
IL10 and TGFB, which reduce the possibility of generating 
an immunoresponse against these.88,92,93
Several methods are used to produce an immunoresponse 
against cancer cells. For example, clinical trials have used 
the systemic administration of such cytokines as IFNs and 
interleukins (ILs) to improve immunity to cancer cells, 
resulting in tumor regression, but with some drawbacks that 
reduced their chances of success. Cytokines are proteins that 
undergo rapid degradation in the circulation after systemic 
administration, which reduces their ability to stimulate an 
immunoresponse against tumor cells. In order to counter 
this systemic degradation, they must be administered in high 
doses to ensure that sufficient cytokines will survive to reach 
the tumor site. However, this method is not practicable, since 
cytokines have been found to be cytotoxic in high doses.92
In order to overcome the limitations of systemic admin-
istration of cytokines, local or targeted administration has 
been tried, with improved results.95 However, cytokine/
protein injections have to be given repeatedly to maintain 
their effect in increasing immunity. One way to eliminate 
the need for repeated injections is to use immunomodulation 
gene therapy, where instead of the proteins, genes encoding 
for cytokines are injected into the patient to promote the 
continuous release of cytokines from the cells.
Two approaches are commonly used for delivery of 
immunomodulatory genes. First, a vector (usually viral) is 
used to deliver a suitable gene to the cancer site, where it 
promotes the continuous release of the cytokine encoded by 
the gene. It thus activates T cells against the tumor antigens, 
resulting in the development of an immunoreaction against 
these tumor cells and their elimination by the immune 
system. The second approach, called cancer vaccine, involves 
introducing the gene encoding the cytokines of interest to 
extracted cancer cells (ex vivo), then reinjecting them into 
the patient, where they elicit an immunoreaction against the 
cancer cells due to the effect of the antigens expressed by 
the injected cells.90–92
Many studies have used genes encoding specific prostate 
antigens to induce an immunoresponse directed against pros-
tate cancer cells only. Xiao et al94 used lentivirus to deliver 
PSCA to prostate cancer. They reported a significant increase 
in CD8 and CD4 T cells after injecting the drug into mice. 
This procedure also showed a possible prophylactic effect 
against tumor growth, as well as a preventive effect against 
metastasis. Similarly, Maurer et al95 investigated the immuno-
stimulatory effect of adding the cytosine–phosphorothioate–
guanine gene to bone-marrow dendritic cells. This produced 
a significant release of IL6 and IL12, making it a potential 
adjuvant for ex vivo vaccination.
Other researchers have upregulated immunoresponse by 
engineering ex vivo prostate cancer cells to hold cytokines 
and/or cytokine-receptor genes so that they respond bet-
ter to cancer cells and provide immunity against cancer. 
Morris et al96 reconstructed murine prostate cancer cells 
(TRAMP-C2) to express IL15 and its specific receptor 
IL15RA, then used them to vaccinate mice. Their results 
showed significant expression of CD8 T cells and natural 
killer cells. Hull et al97 prepared a vaccine to be used in situ 
in mice with the RM9 model of prostate cancer. The vaccine 
contained a combination of two genes encoding IL12 and B71 
carried by an adenovirus. In vivo results after in situ injections 
showed significant suppression of tumor growth.
In 2010, the first ex vivo cancer vaccine, Provenge 
(Dendreon Corporation, Seal Beach, CA) (sipuleucel-T) was 
approved by the US FDA to treat prostate cancer. It targets 
the prostatic acid phosphatase antigen, which is released by 
prostate cancer cells. When the vaccine was used in clinical 
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trials to treat patients at the metastatic stage of the disease, 
a significant increase was found in survival time between 
control and treated groups by up to 4.5 months.98
Nonviral gene delivery systems have also been used to 
upregulate immunoresponse. We demonstrated that treatment 
with a DAB-Lf dendriplex encoding IL12 resulted in tumor 
disappearance of 20% of both PC3 and DU145 prostate 
tumors and tumor regression of 10% on both tumor types.36 
In our experiments, we had to use immunodeficient BALB/c 
mice able to produce B cells, but not T cells, in order for 
them to grow subcutaneous tumors of human origin. We 
thus hypothesize that the therapeutic effect could be further 
enhanced by using a fully immunocompetent mouse bear-
ing a murine prostate-tumor model. Other studies have also 
demonstrated the ability of IL12-encoding DNA to induce 
a therapeutic effect on prostate tumors, but using different 
modalities of treatment: intratumoral injection, use of a virus 
as a delivery system or cotreatment with mifepristone,99 
radiotherapy,100 oncolytic herpes simplex viruses,101 adeno-
viral vector-mediated herpes simplex virus–thymidine kinase 
and ganciclovir (Gcv).102 These studies mainly showed a 
slowdown in prostate tumor growth, rather than the tumor 
regression observed in some instances in our experiments.
Suicide gene therapy
One of the most important approaches in gene therapy is 
suicide gene therapy, the purpose of which is to destroy cancer 
cells selectively without harming normal ones. It is based on 
the principle of delivering a specific gene that encodes an 
enzyme able to convert prodrugs in cancer cells into cytotox-
ins that destroy the host cells.103,104 Two main genes encoding 
enzymes have been examined extensively in prostate cancer 
suicide therapy: Escherichia coli cytosine deaminase (CD), 
which has the ability to convert the prodrug 5-fluorocytosine 
(5FC) to 5-fluorouracil (5FU) and the herpes simplex virus-
thymidine kinase gene (HSV TK), which converts the prodrug 
Gcv to Gcv mono- or triphosphate.102,105
The main advantage of this therapeutic approach is the 
bystander effect, which can be defined as the ability of the 
activated prodrug to induce a cytotoxic effect in the tar-
geted cells, as well as other surrounding cancer cells, thus 
creating a killing zone around the cells transfected with the 
suicide gene.106 This effect may be due to passive transport, 
gap junctions, and stimulation in the microenvironment of 
the tumor site.105 The HSV TK-GCV suicide gene therapy 
system has been found to have this bystander effect, which 
is probably due to the intracellular diffusion of the activated 
prodrug Gcv triphosphate through the gap junctions between 
adjacent cells. However, the bystander effect of the HSV 
TK-GCV system is considerably weaker than that of CD5-
FU.105,106 The CD-5FU suicide-gene therapy system has 
been found to have a significant bystander effect. It diffuses 
readily through the tumor site without the need of cell–cell 
adhesion, which has been attributed to the ability of this 
system to stimulate the immune system against cancer cells 
by activating the natural killer cells CD8 and CD4, making 
it more efficacious to treat metastasized tumors.104,105
The combination of the two suicide-therapy systems 
has been found to improve therapeutic results on prostate 
cancer. Yoshimura et al107 measured the therapeutic effects 
of HSV TK-Gcv and CD-5FC alone and in combination using 
a cationic lipid as vector in the LNCaP prostate cancer cell 
line. Each system alone gave around a 60% decrease in cell 
viability, while in combination they killed 77% of LNCaP 
cells. Similarly, HSV TK and CD genes were constructed 
together in pIRES plasmid, the Cytomegalovirus promoter 
of which was replaced by PSMA to achieve more specific 
targeting to prostate cancer cells. In vitro results in LNCaP 
and PC3 cell lines showed 70% and 60% growth inhibition, 
respectively. These results were improved compared to those 
observed with either therapy alone.108
Conclusion
Prostate cancer remains one of the most significant therapeutic 
challenges to address in the coming years. Although several 
standard therapies, such as prostatectomy, hormone therapy, 
chemotherapy, and radiotherapy, are currently available in the 
clinic, there is currently no effective treatment for advanced 
prostate cancer. In order to overcome this issue, novel gene-
based therapeutic approaches are rapidly evolving and rep-
resent promising strategies for the treatment of this cancer. 
The use of highly efficient, safe, tumor-targeted delivery 
systems able to carry therapeutic pDNA exploiting various 
therapeutic strategies has been proven to be a novel and effec-
tive approach to treat prostate cancer. These nanomedicines 
may thus represent a new promising avenue for the treatment 
of prostate cancer and should be further investigated.
Disclosure
This study was financially supported by a grant from World-
Cancer Research (grant 16 – 1303) to CD. NA is in receipt 
of a PhD studentship from the Saudi Cultural Bureau and 
Princess Nourah bint Abdulrahman University (Kingdom 
of Saudi Arabia). SS is funded by a research grant from the 
Dunhill Medical Trust (grant R463/0216). The authors report 
no other conflicts of interest in this work.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
9.
82
.1
79
 o
n 
26
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5765
Targeted nonviral gene therapy in prostate cancer
References
 1. International Agency for Research on Cancer. All cancers (exclud-
ing non-melanoma skin cancer): estimated incidence, mortality and 
prevalence worldwide in 2012. Available from: http://globocan.iarc.
fr/Pages/fact_sheets_cancer.aspx. Accessed November 30, 2017.
 2. Cancer Research UK. Prostate cancer incidence statistics. 2015. Avail-
able from: http://www.cancerresearchuk.org/cancer-info/cancerstats/
types/prostate/incidence/uk-prostate-cancer-incidence-statistics. 
Accessed November 19, 2017.
 3. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy 
clinical trials. Mol Ther. 2007;15:1042–1052.
 4. Philippou Y, Dev H, Sooriakumaran P. Diagnosis and screening. In: 
Tewari AK, Whelan P, Graham JD, editors. Prostate Cancer: Diag-
nosis and Clinical Management. Chichester: John Wiley & Sons; 
2014:16–33.
 5. Bagnall P. Diagnosis and treatment of prostate cancer. Nurs Times. 
2014;110:12–15.
 6. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 
2013;525:162–169.
 7. Wang WW, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. 
Curr Pharm Biotechnol. 2013;14:46–60.
 8. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. 
Gene medicine for cancer treatment: commercially available medi-
cine and accumulated clinical data in China. Drug Des Devel Ther. 
2009;2:115–122.
 9. Ogris M, Wagner E. Targeting tumors with non-viral gene delivery 
systems. Drug Discov Today. 2002;7:479–485.
 10. McCrudden CM, McCarthy HO. Cancer gene therapy: key biological 
concepts in the design of multifunctional non-viral delivery systems. 
In: Molina F, editor. Gene Therapy: Tools and Potential Applications. 
London: InTech; 2013:213–248.
 11. Gao HJ, Shi WD, Freund LB. Mechanics of receptor-mediated endo-
cytosis. Proc Natl Acad Sci U S A. 2005;102:9469–9474.
 12. Pérez-Martínez FC, Guerra J, Posadas I, Ceña V. Barriers to non-viral 
vector-mediated gene delivery in the nervous system. Pharm Res. 2011; 
28:1843–1858.
 13. Taira K, Kataoka K, Niidome T. Non-Viral Gene Therapy: Gene Design 
and Delivery. Heidelberg: Springer; 2005.
 14. Mctaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. 
Biotechnol Adv. 2002;20:1–31.
 15. Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery 
systems. Pharmaceut Med. 2011;25:293–306.
 16. Curiel DT, Douglas JT. Cancer Gene Therapy. Totowa (NJ): Humana 
Press; 2005.
 17. Shan Y, Luo T, Peng C, et al. Gene delivery using dendrimer-
entrapped gold nanoparticles as nonviral vectors. Biomaterials. 
2012;33:3025–3035.
 18. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 
1997;54:8–14.
 19. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, 
lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 
1987;84:7413–7417.
 20. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-
sized particles and molecules as imaging agents: considerations and 
caveats. Nanomedicine (Lond). 2008;3:703–717.
 21. Bendas G. Immunoliposomes: a promising approach to targeting cancer 
therapy. Biodrugs. 2001;15:215–224.
 22. Fasbender A, Marshall J, Moninger TO, Grunst T, Cheng S, Welsh MJ. 
Effect of co-lipids in enhancing cationic lipid-mediated gene transfer 
in vitro and in vivo. Gene Ther. 1997;4:716–725.
 23. Mastrobattista E, Hennink WE. Polymers for gene delivery: charged 
for success. Nat Mater. 2012;11:10–12.
 24. Männistö M, Vanderkerken S, Toncheva V, et al. Structure-activity 
relationships of poly(L-lysines): effects of pegylation and molecular 
shape on physicochemical and biological properties in gene delivery. 
J Control Release. 2002;83:169–182.
 25. Lemkine GF, Demeneix BA. Polyethylenimines for in vivo gene 
delivery. Curr Opin Mol Ther. 2001;3:178–182.
 26. Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, 
Andresen TL. The possible “proton sponge” effect of polyethylenimine 
(PEI) does not include change in lysosomal pH. Mol Ther. 2013;21: 
149–157.
 27. Lynn DM, Langer R. Degradable poly(B-amino esters): synthesis, 
characterization, and self-assembly with plasmid DNA. J Am Chem 
Soc. 2000;122:10761–10768.
 28. Buhleier E, Wehner W, Vögtle F. “Cascade”- and “nonskid-chain-
like” syntheses of molecular cavity topologies. Synthesis. 1978;2: 
155–158.
 29. Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: 
starburst-dendritic macromolecules. Polym J. 1985;17:117–132.
 30. Klajnert B, Bryszewska M. Dendrimers: properties and applications. 
Acta Biochim Pol. 2001;48:199–208.
 31. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. 
Adv Drug Deliv Rev. 2005;57:2177–2202.
 32. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotech-
nology: the impact of passive and active targeting in the era of modern 
cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
 33. Wally J, Buchanan SK. A structural comparison of human serum 
transferrin and human lactoferrin. Biometals. 2007;20:249–262.
 34. Al Robaian M, Chiam KY, Blatchford DR, Dufès C. Therapeutic effi-
cacy of intravenously administered transferrin-conjugated dendriplexes 
on prostate carcinomas. Nanomedicine (Lond). 2014;9:421–434.
 35. Shankaranarayanan JS, Kanwar JR, Al-Juhaishi AJ, Kanwar RK. 
Doxorubicin conjugated to immunomodulatory anticancer lactoferrin 
displays improved cytotoxicity overcoming prostate cancer chemo 
resistance and inhibits tumour development in TRAMP mice. Sci Rep. 
2016;6:32062.
 36. Altwaijry N, Somani S, Parkinson JA, et al. Regression of prostate 
tumors after intravenous administration of lactoferrin-bearing polypro-
pylenimine dendriplexes encoding TNF-A, TRAIL, and interleukin-12. 
Drug Deliv. 2018;25:679–689.
 37. Liu Z, Wang F, Chen X, Integrin A
v
B
3
-targeted cancer therapy. Drug 
Dev Res. 2008;69:329–339.
 38. Marelli UK, Rechenmacher F, Sobahi TR, Mas-Moruno C, Kessler H. 
Tumor targeting via integrin ligands. Front Oncol. 2013;3:222.
 39. Bonkhoff H, Stein U, Remberger K. Differential expression of A6 and 
A2 very late antigen integrins in the normal, hyperplastic, and neoplastic 
prostate: simultaneous demonstration of cell surface receptors and their 
extracellular ligands. Hum Pathol. 1993;24:243–248.
 40. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer 
metastases. Cancer Metastasis Rev. 2001;20:321–331.
 41. Suyin PC, Dickinson JL, Holloway AF. Integrins in prostate cancer 
invasion and metastasis. In: Hamilton G, editor. Advances in Prostate 
Cancer. Rijeka, Croatia: InTech; 2013:621–639.
 42. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic 
carcinoma cell migration via A
v
B
3
 integrin is modulated by a focal adhe-
sion kinase pathway. Cancer Res. 1999;59:1655–1664.
 43. Stachurska A, Elbanowski J, KowalczyĔska HM. Role of A5B1 and 
AvB3 integrins in relation to adhesion and spreading dynamics of pros-
tate cancer cells interacting with fibronectin under in vitro conditions. 
Cell Biol Int. 2012;36:883–892.
 44. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal-antibodies 
to a new antigenic marker in epithelial prostatic cells and serum of 
prostatic-cancer patients. Anticancer Res. 1987;7:927–936.
 45. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-
specific membrane antigen in normal and malignant human tissues. 
World J Surg. 2006;30:628–636.
 46. Shen D, Xie F, Edwards WB. Evaluation of phage display discovered 
peptides as ligands for prostate-specific membrane antigen (PSMA). 
PLoS One. 2013;8:68339.
 47. Dassie JP, Hernandez LI, Thomas GS, et al. Targeted inhibition of 
prostate cancer metastases with an RNA aptamer to prostate-specific 
membrane antigen. Mol Ther. 2014;22:1910–1922.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
9.
82
.1
79
 o
n 
26
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5766
Altwaijry et al
 48. Goodman OB, Barwe SP, Ritter B, et al. Interaction of prostate specific 
membrane antigen with clathrin and the adaptor protein complex-2. 
Int J Oncol. 2007;31:1199–1203.
 49. Laidler P, DuliĔska J, Lekka M, Lekki J. Expression of prostate specific 
membrane antigen in androgen-independent prostate cancer cell line 
PC-3. Arch Biochem Biophys. 2005;435:1–14.
 50. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric 
peptide that binds selectively to prostate-specific membrane antigen and 
inhibits its enzymatic activity. Cancer Res. 2006;66:9171–9177.
 51. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate can-
cer targeting motifs: expression of ANB3, neurotensin receptor 1, pros-
tate specific membrane antigen, and prostate stem cell antigen in human 
prostate cancer cell lines and xenografts. Prostate. 2012;72:523–532.
 52. Garcia-Hernandez ML, Gray A, Hubby B, Klinger OJ, Kast WM. 
Prostate stem cell antigen vaccination induces a long-term protective 
immune response against prostate cancer in the absence of autoim-
munity. Cancer Res. 2008;68:861–869.
 53. Sharifi N, Salmaninejad A, Ferdosi S, et al. HER2 gene amplification in 
patients with prostate cancer: evaluating a CISH-based method. Oncol 
Lett. 2016;12:4651–4658.
 54. Rabiau N, Dechelotte P, Guy L, et al. Immunohistochemical staining 
of mucin 1 in prostate tissues. In Vivo. 2009;23:203–207.
 55. Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss 
of retinoblastoma gene expression in human prostate carcinoma. Proc 
Natl Acad Sci U S A. 1990;87:7762–7766.
 56. Mazhar D, Waxman J. Gene therapy for prostate cancer. BJU Int. 2004; 
93:465–469.
 57. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ. 
Gene therapy for prostate cancer. Urology. 2001;57:8–16.
 58. Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular 
apoptosis machinery. Cancer Treat Rev. 2012;38:868–876.
 59. Walczak H. Death receptor-ligand systems in cancer, cell death, and 
inflammation. Cold Spring Harb Perspect Biol. 2013;5:a008698.
 60. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp 
Clin Cancer Res. 2011;30:87.
 61. Tüting T, Gambotto A, Baar J, et al. Interferon-A gene therapy for 
cancer: retroviral transduction of fibroblasts and particle-mediated 
transfection of tumor cells are both effective strategies for gene delivery 
in murine tumor models. Gene Ther. 1997;4:1053–1060.
 62. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced 
apoptosis: potentiation by inhibition of NF-KB. Science. 1996; 
274:784–787.
 63. van Horssen R, ten Hagen TL, Eggermont AM. TNF-A in cancer 
treatment: molecular insights, antitumor effects, and clinical utility. 
Oncologist. 2006;11:397–408.
 64. Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-A-mediated 
apoptosis, in normal human prostate epithelial cells and tumor cell lines. 
Cancer Lett. 2004;203:145–154.
 65. Mauceri HJ, Hanna NN, Wayne JD. Tumor necrosis factor A (TNF-A) 
gene therapy targeted by ionizing radiation selectively damages tumor 
vasculature. Cancer Res. 1996;56:4311–4314.
 66. Tandle A, Hanna E, Lorang D, et al. Tumor vasculature-targeted deliv-
ery of tumor necrosis factor-A. Cancer. 2009;115:128–139.
 67. Chung TD, Mauceri HJ, Hallahan DE, et al. Tumor necrosis factor-
alpha-based gene therapy enhances radiation cytotoxicity in human 
prostate cancer. Cancer Gene Ther. 1998;5:344–349.
 68. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis 
factor-induced nuclear factor (NF)-KB activation and induction of 
apoptosis by apigenin in human prostate carcinoma PC-3 cells: corre-
lation with down-regulation of NF-KB-responsive genes. Clin Cancer 
Res. 2004;10:3169–3178.
 69. Shi J, Chen J, Serradji N, et al. PMS1077 sensitizes TNF-A induced 
apoptosis in human prostate cancer cells by blocking NF-KB signaling 
pathway. PLoS One. 2013;8:e61132.
 70. Barresi G, Tuccari G. Lactoferrin in benign hypertrophy and carcinomas 
of the prostatic gland. Virchows Arch A Pathol Anat Histopathol. 1984; 
403:59–66.
 71. Tuccari G, Barresi G. Lactoferrin in human tumours: immunohistochem-
ical investigations during more than 25 years. Biometals. 2011;24: 
775–784.
 72. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of 
recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–162.
 73. Norian L, James B, Griffith T. Advances in viral vector-based TRAIL 
gene therapy for cancer. Cancers. 2011;3:603–620.
 74. Griffith T, Stokes B, Kucaba T, et al. TRAIL gene therapy: from pre-
clinical development to clinical application. Curr Gene Ther. 2009;9: 
9–19.
 75. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. Tumor necrosis factor-
related apoptosis-inducing ligand-mediated apoptosis in androgen-
independent prostate cancer cells. Cancer Res. 2000;60:2384–2389.
 76. Farooqi AA, de Rosa G. TRAIL and microRNAs in the treatment of 
prostate cancer: therapeutic potential and role of nanotechnology. Appl 
Microbiol Biotechnol. 2013;97:8849–8857.
 77. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. 
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing 
ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 
2000;165:2886–2894.
 78. Lin T, Zhang L, Davis J, et al. Combination of TRAIL gene therapy 
and chemotherapy enhances antitumor and antimetastasis effects 
in chemosensitive and chemoresistant breast cancers. Mol Ther. 
2003;8:441–448.
 79. Seol JY, Park KH, Hwang CI, et al. Adenovirus-TRAIL can overcome 
TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 
2003;10:540–548.
 80. Mohr A, Henderson G, Dudus L, et al. AAV-encoded expression of 
TRAIL in experimental human colorectal cancer leads to tumor regres-
sion. Gene Ther. 2004;11:534–543.
 81. Chen Z, Penet MF, Krishnamachary B, et al. PSMA-specific theranostic 
nanoplex for combination of TRAIL gene and 5-FC prodrug therapy 
of prostate cancer. Biomaterials. 2016;80:57–67.
 82. Elojeimy S, Mckillop JC, el-Zawahry AM, et al. FasL gene therapy: 
a new therapeutic modality for head and neck cancer. Cancer Gene 
Ther. 2006;13:739–745.
 83. Xiong L, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-
restricted replicative adenovirus enhances safety and antitumor efficacy. 
Clin Cancer Res. 2007;13:5463–5473.
 84. Nakanishi H, Mazda O, Satoh E, et al. Nonviral genetic transfer of 
Fas ligand induced significant growth suppression and apoptotic 
tumor cell death in prostate cancer in vivo. Gene Ther. 2003;10: 
434–442.
 85. Hyer ML, Sudarshan S, Schwartz DA, et al. Quantification and 
characterization of the bystander effect in prostate cancer cells fol-
lowing adenovirus-mediated FasL expression. Cancer Gene Ther. 
2003;10:330–339.
 86. Xiong L, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-
restricted replicative adenovirus enhances safety and antitumor efficacy. 
Clin Cancer Res. 2007;13:5463–5473.
 87. Hedlund TE, Meech SJ, Srikanth S, et al. Adenovirus-mediated expres-
sion of Fas ligand induces apoptosis of human prostate cancer cells. 
Cell Death Differ. 1999;6:175–182.
 88. Agha-Mohammadi S, Lotze MT. Immunomodulation of cancer: 
potential use of selectively replicating agents. J Clin Invest. 2000; 
105:1173–1176.
 89. Mabjeesh N, Zhong H, Simons JW. Gene therapy of prostate cancer: 
current and future directions. Endocr Relat Cancer. 2002;9:115–139.
 90. Sharma B, Ma W, Adjei IM, et al. Nanoparticle-mediated p53 gene 
therapy for tumor inhibition. Drug Deliv Transl Res. 2011;1:43–52.
 91. Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/
TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using 
transferrin-facilitated lipofection gene delivery strategy. Hum Gene 
Ther. 2002;13:761–773.
92. Burdelski C, Dieckmann T, Heumann A, et al. p16 upregulation is linked 
to poor prognosis in ERG negative prostate cancer. Tumor Biology. 
2016;37:12655–12663.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
9.
82
.1
79
 o
n 
26
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
5767
Targeted nonviral gene therapy in prostate cancer
 93. Shalev M, Thompson TC, Kadmon D, et al. Gene therapy for prostate 
cancer. Urology. 2001;57:8–16.
 94. Xiao L, Joo KI, Lim M, Wang P. Dendritic cell-directed vaccination 
with a lentivector encoding PSCA for prostate cancer in mice. PLoS 
One. 2012;7:e48866.
 95. Maurer T, Pournaras C, Aguilar-Pimentel JA, et al. Immunostimulatory 
CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic 
T cell responses. Urol Oncol. 2013;31:1395–1401.
 96. Morris JC, Ramlogan-Steel CA, Yu P, et al. Vaccination with tumor 
cells expressing IL-15 and IL-15RA inhibits murine breast and prostate 
cancer. Gene Ther. 2014;21:393–401.
 97. Hull GW, Mccurdy MA, Nasu Y, et al. Prostate cancer gene therapy: 
comparison of adenovirus-mediated expression of interleukin 12 with 
interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, 
cell-based vaccines. Clin Cancer Res. 2000;6:4101–4109.
 98. Cheever MA, Higano CS. Provenge (sipuleucel-T) in prostate cancer: 
the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 
2011;17:3520–3526.
 99. Gabaglia C, Delaney A, Gee J, et al. Treatment combining RU486 
and Ad5IL-12 vector attenuates the growth of experimentally formed 
prostate tumors and induces changes in the sentinel lymph nodes of 
mice. J Transl Med. 2010;8:98.
 100. Fujita T, Timme TL, Tabata K, et al. Cooperative effects of adenoviral 
vector-mediated interleukin 12 gene therapy with radiotherapy in a 
preclinical model of metastatic prostate cancer. Gene Ther. 2007;14: 
227–236.
 101. Varghese S, Rabkin SD, Liu R, et al. Enhanced therapeutic efficacy 
of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus 
for transgenic mouse derived prostate cancers. Cancer Gene Ther. 
2006;13:253–265.
 102. Nasu Y, Bangma CH, Hull GW, et al. Combination gene therapy with 
adenoviral vector-mediated HSV-tk  GCV and IL-12 in an orthotopic 
mouse model for prostate cancer. Prostate Cancer Prostatic Dis. 
2001;4:44–55.
 103. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for 
prostate cancer. Adv Drug Deliv Rev. 2009;61:572–588.
 104. Kim KM, Won YW, Adhikary PP, Hwang YM, Kim YH. Suicidal 
gene therapy against tumor using reducible poly (oligo-d-arginine). 
J Control Release. 2011;152:e148–e149.
 105. Zarogoulidis P, Darwiche K, Sakkas A, et al. Suicide gene therapy for 
cancer: current strategies. J Genet Syndr Gene Ther. 2013;4:16849.
 106. Sato T, Neschadim A, Lavie A, Yanagisawa T, Medin JA. The engi-
neered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers 
efficient bystander cell killing for suicide gene therapy of cancer. PLoS 
One. 2013;8:e78711.
 107. Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M. Adeno-
virus mediated prostate specific enzyme prodrug gene therapy using 
prostate specific antigen promoter enhanced by the Cre-loxP system. 
J Urol. 2002;168:2659–2664.
 108. Yue QH, Hu XB, Yin Y, et al. Inhibition of prostate cancer by suicide 
gene targeting the FCY1 and HSV-TK genes. Oncol Rep. 2009;22: 
1341–1347.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
9.
82
.1
79
 o
n 
26
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
